This week, the overall grades of 19 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Eli Lilly and Company’s (LLY) rating worsens to a D from the company’s C rating a week ago. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. For more information, get Portfolio Grader’s complete analysis of LLY stock.

Prestige Brands Holdings, Inc. (PBH) earns a D this week, moving down from last week’s grade of C. Prestige Brands Holdings, Inc. distributes over-the-counter healthcare and household cleaning products to retail stores in the United States, Canada and other international markets. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PBH stock.

Mylan N.V. (MYL) gets weaker ratings this week as last week’s C drops to a D. Mylan N.V. is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock.

Akorn, Inc. (AKRX) declines this week from a C to a D. Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of AKRX stock.

Horizon Pharma plc (HZNP) experiences a ratings drop this week, going from last week’s C to a D. Horizon Pharma plc is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of HZNP stock.

This is a rough week for NeuroDerm Ltd. (NDRM). The company’s rating falls to F from the previous week’s D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of NDRM stock.

Paratek Pharmaceuticals Inc (PRTK) slips from a D to a F this week. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Sucampo Pharmaceuticals, Inc. Class A’s (SCMP) rating weakens this week, dropping to a F versus last week’s D. Sucampo Pharmaceuticals, Inc. Class A is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of SCMP stock.

Slipping from a B to a D rating, Omeros Corporation (OMER) takes a hit this week. Omeros Corporation is a biopharmaceutical company developing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of OMER stock.

Aratana Therapeutics, Inc. (PETX) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PETX stock.

This week, Foamix Pharmaceuticals Ltd. (FOMX) drops from a C to a D rating. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of FOMX stock.

Teligent, Inc. (TLGT) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in operating margin growth, earnings growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of TLGT stock.

This week, Neos Therapeutics, Inc. (NEOS) drops from a D to a F rating. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NEOS stock.

Ocular Therapeutix Inc (OCUL) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OCUL stock.

AcelRx Pharmaceuticals, Inc. (ACRX) declines this week from a C to a D. AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACRX stock.

This is a rough week for BioDelivery Sciences International, Inc. (BDSI). The company’s rating falls to F from the previous week’s D. BioDelivery Sciences International, Inc. is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BDSI stock.

Slipping from a C to a D rating, Auris Medical Holding AG (EARS) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of EARS stock.

This week, DURECT Corporation’s (DRRX) rating worsens to a D from the company’s C rating a week ago. DURECT Corporation is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of DRRX stock.

Jaguar Animal Health, Inc. (JAGX) slips from a C to a D this week. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of JAGX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.